



MEDI-CAL DRUG USE REVIEW (DUR) BOARD

**State of California
DEPARTMENT OF HEALTH CARE SERVICES**

Notice is hereby given that the **Medi-Cal DUR Board** will conduct a public meeting on **Tuesday, September 20, 2016**, at the following location:

Xerox State Healthcare, LLC
840 Stillwater Road, Monterey Room
West Sacramento, CA 95605

Medi-Cal Drug Use Review Board
Meeting Agenda
September 20, 2016
9:30 AM-12:30 PM

Report Type*	Agenda Item	Presenter	Time
C	1. Welcome/Introduction	Pauline Chan, RPh, MBA	930-945
A	2. Call to Order/Review and Approval of Previous Minutes from May 17, 2016	Robert Mowers, PharmD	945-950
	3. Old Business		
A	a. Review of Action Items from Previous Board Meeting: i. Pregnancy Alert: Updated ii. Drug-Drug Interaction Alert: DUR Manual Updated iii. Anticholinergic Provider Letter: Sent iv. PCSK9 Inhibitor: Update RetroDUR in May 2017	Pauline Chan, RPh, MBA	950-955
	4. New Business		
R/A/D	a. Board Activities	DUR Board	955-1000
R/D	b. Managed Care Presentation: San Francisco Health Plan	Eileen Yamada, MD, MPH [Public Health Medical Officer, Technical Assistance Section, Immunization Branch California Department of Public Health]	1000-1020
R/A/D	c. Presentation: Medi-Cal Payment Error Study	Mark P. Mimnaugh, RN, CCRN, MPA [Chief, Medical Review Branch Audits and Investigations Division]	1020-1040

R/A/D	d. FFY2015 DUR Annual Report to CMS	Pauline Chan, RPh, MBA and Ivana Thompson, PharmD	1040- 1100
R/A	e. Quarterly Report: 2Q2016 (April – June 2016) f. Review of Physician Administered Drugs (PADs): 1Q2016 (January – March 2016) g. Prospective DUR i. Review of DUR Alerts for New GCNs: 2Q2016 h. Review of DUR Educational Outreach to Providers i. Update: Anticholinergic Letter ii. Updated Outcomes: Asthma Letter iii. Updated Outcomes: MEDD Letter iv. Proposal: Buprenorphine Letter i. Policy Impact Report: Antipsychotic TAR Requirement for Children and Adolescents	Amanda Fingado, MPH	1100- 1140
R/A/D	j. Retrospective DUR i. HIV Antiretroviral Drugs k. Review of DUR Publications i. DUR Educational Bulletin (August, 2016): Buprenorphine ii. Discussion/Recommendations for Future Bulletins	Shalini Lynch, PharmD	1140- 1200
	l. Pharmacy Update i. CMS Update 1. Antipsychotic Drug Use in Children (ADC) Affinity Group 2. Prescription Opioids Abuse Actions 3. 2018 CMS DUR Annual Report Planning Committee ii. DHCS Quality Strategy Annual Update iii. Child Core Set Measures iv. Adult Core Set Measures v. Academic Detailing Conference Working Agenda	Pauline Chan, RPh, MBA	1200- 1225
C	5. Public Comments		1225- 1230
	6. Consent Agenda		
I	a. Meeting feedback b. Next meeting: November 15, 2016 9:30 AM -12:30 PM DHCS Training Rooms B+C 1500 Capitol Avenue Sacramento, CA 95814 c. Proposed DUR Board Meeting Dates for 2017: Tuesday, February 21, 2017 Tuesday, May 16, 2017 Tuesday, September 19, 2017 Tuesday, November 21, 2017		
	7. Adjournment		1230

* REPORT TYPE LEGEND: **A: Action; R: Report; I: Information; C: Comment; D: Discussion**

** Comments from the public are always appreciated. However, comments will be limited to five minutes per individual.

Picture identification is required to gain access into the California Department of Health Services building. However, your security information will not be provided to the DUR Board.

You can obtain the DUR Board agenda from the Medi-Cal DUR Main Menu Web site (http://files.medi-cal.ca.gov/pubsdoco/dur/dur_home.asp).